Advertisement

Topics

Physiomics’ Virtual Tumour software starting to gain traction in world of oncology

02:30 EDT 5 Jul 2019 | Proactive Investors

Here we take a closer look at Physiomics, the AIM company that owns a piece of software called Virtual Tumour that predicts the effects of drugs on cancers

Original Article: Physiomics’ Virtual Tumour software starting to gain traction in world of oncology

NEXT ARTICLE

More From BioPortfolio on "Physiomics’ Virtual Tumour software starting to gain traction in world of oncology"

Advertisement
Quick Search
Advertisement
Advertisement